BIODESIX Q1 Revenue Jumps 42% to $25.6M; Net Loss Narrows to $7.8M

Biodesix Inc. reported a significant increase in revenue for the first quarter of 2026, rising 42.3% to $25.6 million, while narrowing its net loss to $7.8 million from $11.1 million in the prior year. The company also saw its net loss per share improve to $(0.81) from $(1.52). Cash and cash equivalents increased to $25.6 million, largely supported by $17.2 million in proceeds from the issuance of common stock through financing activities. This quarter marks a shift to positive stockholders' equity of $9.1 million from a deficit of $2.5 million at the end of 2025, despite an increase in net cash used in operating activities.